Real-World Outcomes of Lenvatinib in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Multicentre Retrospective Study

Abstract

Simple Summary Lenvatinib is an established treatment for radioactive iodine-refractory differentiated thyroid cancer, but long-term real-world data remain limited, particularly in Asian populations. In this multicentre study across seven public hospitals in Hong Kong, we evaluated the effectiveness and safety of lenvatinib in 82 patients. Despite the frequent use of reduced starting doses, lenvatinib demonstrated durable clinical activity with manageable toxicity. Dose reduction and temporary treatment interruption were common and often allowed treatment continuation following adverse events. These findings provide real-world evidence on treatment patterns and outcomes in routine practice and suggest that careful toxicity management may facilitate long-term treatment delivery.